Breast Cancer Clinical Trial

Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition

Summary

There are several approved and guideline-recommended treatments for metastatic, estrogen receptor-positive breast cancer that has progressed on an aromatase inhibitor and a CDK4/6 inhibitor. Right now, doctors do not have a good way of choosing between these treatments. Scientists we work with have come up with ways to use the biology of the tumor to try to predict which treatment is best. This study is being done to test if those predictions are right and to learn more about these tumors to design better treatments in the future.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologic diagnosis of breast cancer
Metastatic or incurable
Prior treatment with an anastrozole or letrozole and a CDK4/6 inhibitor
Progression while on or within 6 months of stopping the CDK4/6 inhibitor
At least one lesion amenable to percutaneous biopsy that is not a purely sclerotic bone lesion
ECOG 0-2
Age 18 or greater
Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

Prior treatment within 2 years with fulvestrant, alpelisib, everolimus, or capecitabine
Comorbid disease other than breast cancer with a life expectancy of less than 2 years
Cancer other than breast cancer that is expected to need treatment within 2 years
Platelets < 100,000/microliter
INR > 1.5

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

74

Study ID:

NCT04965688

Recruitment Status:

Recruiting

Sponsor:

Inova Health Care Services

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Inova Schar Cancer Institute
Fairfax Virginia, 22031, United States More Info
Stephanie Van Bebber, MSc.
Contact
571-472-0213
[email protected]
Carrie Fischer, MS
Contact
571-471-0224
[email protected]
Adam Cohen, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Phase:

Phase 2

Estimated Enrollment:

74

Study ID:

NCT04965688

Recruitment Status:

Recruiting

Sponsor:


Inova Health Care Services

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider